Nucleix
Bringing deep knowledge in computer science, bioinformatics, and statistical analysis, Adam co-founded Nucleix and has been an instrumental part of building the company from its inception. Together with Danny, he co-developed a non-invasive high-resolution method for determination of cell lineage based on analysis of somatic DNA mutations, resulting in the establishment of an international lineage center at the Weizmann Institute. Adam is the author of 9 scientific papers and co-inventor of several patents. Adam holds a Ph.D. in Life Sciences from the Weizmann Institute, and a B.A in Computer Sciences cum laude and Music from Tel-Aviv University.
This person is not in any offices
Nucleix
Nucleix is a global leader in creating cancer diagnostic panels based on epigenetic biomarkers. Backed by OrbiMed and other leading investors, Nucleix provides a strong pipeline of products for various cancer types.